Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element

The Journal of Clinical Investigation
Thierry ClaudelBart Staels

Abstract

Serum levels of HDL are inversely correlated with the risk of coronary heart disease. The anti-atherogenic effect of HDL is partially mediated by its major protein constituent apoA-I. In this study, we identify bile acids that are activators of the nuclear receptor farnesoid X receptor (FXR) as negative regulators of human apoA-I expression. Intrahepatocellular accumulation of bile acids, as seen in patients with progressive familial intrahepatic cholestasis and biliary atresia, was associated with diminished apoA-I serum levels. In human apoA-I transgenic mice, treatment with the FXR agonist taurocholic acid strongly decreased serum concentrations and liver mRNA levels of human apoA-I, which was associated with reduced serum HDL levels. Incubation of human primary hepatocytes and hepatoblastoma HepG2 cells with bile acids resulted in a dose-dependent downregulation of apoA-I expression. Promoter mutation analysis and gel-shift experiments in HepG2 cells demonstrated that bile acid-activated FXR decreases human apoA-I promoter activity by a negative FXR response element mapped to the C site. FXR bound this site and repressed transcription in a manner independent of retinoid X receptor. The nonsteroidal synthetic FXR agonist GW4...Continue Reading

References

Jan 15, 1987·Biochemical and Biophysical Research Communications·R BarbarasG Ailhaud
Nov 1, 1987·Atherosclerosis·P PuchoisJ C Fruchart
Oct 1, 1970·Journal of Clinical Pathology·G M MurphyD N Baron
Nov 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·N C BirnbergE Herbert
Jan 1, 1994·European Journal of Clinical Pharmacology·E HagenM C Wolf
Dec 15, 1995·Cell·D J Mangelsdorf, R M Evans
Apr 1, 1996·Current Opinion in Lipidology·P J Barter, K A Rye
Aug 1, 1997·Current Opinion in Lipidology·L O Andersson
May 21, 1999·Science·M MakishimaB Shan
May 21, 1999·Science·D J ParksJ M Lehmann
Jun 9, 1999·Proceedings of the National Academy of Sciences of the United States of America·M NittaB Shan
Jun 9, 1999·Molecular Cell·H WangB M Forman
Jan 25, 2000·The Journal of Biological Chemistry·A BonazziM Laniado-Schwartzman
Aug 24, 2000·Journal of Medicinal Chemistry·P R MaloneyT M Willson
Mar 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·J L StaudingerS A Kliewer
Mar 27, 2001·Current Opinion in Lipidology·G Schmitz, T Langmann
Jun 2, 2001·The Journal of Biological Chemistry·M AnanthanarayananF J Suchy

❮ Previous
Next ❯

Citations

Apr 8, 2010·Pharmaceutical Research·Subhajit Mukherjee, Sridhar Mani
Apr 29, 2010·Current Diabetes Reports·Bart StaelsVivian Fonseca
Dec 24, 2013·European Journal of Pharmacology·Yuichiro AmanoRyuichi Tozawa
Aug 2, 2003·Gastroenterology·Thierry ClaudelBart Staels
Feb 11, 2009·The Journal of Biological Chemistry·Theo H van DijkFolkert Kuipers
May 21, 2010·Nucleic Acids Research·Hansook Kim ChongTimothy F Osborne
Apr 12, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Yuan LuAnna Radominska-Pandya
Sep 5, 2008·Journal of Virology·Christophe RamièrePatrice André
Jul 3, 2002·The Journal of Clinical Investigation·Clive R PullingerJohn P Kane
Mar 25, 2006·The Journal of Clinical Investigation·Ke MaDavid D Moore
Aug 2, 2011·The Journal of Clinical Investigation·Indumathi ChennamsettyGert M Kostner
May 3, 2012·Journal of Lipid Research·Geoffrey PorezBart Staels
Feb 4, 2010·PloS One·Sohela ShahLaura N Bull
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Ronald B Goldberg
May 13, 2014·Biochimica Et Biophysica Acta·Panagiota Karagianni, Iannis Talianidis
Aug 15, 2006·FEBS Letters·Salvatore Modica, Antonio Moschetta
Sep 17, 2013·Journal of Cellular Biochemistry·Shant ParseghianMichael J Haas
Jan 15, 2015·Toxicology and Applied Pharmacology·Peizhen SongCurtis D Klaassen
Nov 19, 2015·Acta Pharmaceutica Sinica. B·Lili DingWendong Huang
Jul 25, 2012·Clinics in Liver Disease·Tommy Pacana, Michael Fuchs
Jul 12, 2011·Atherosclerosis·Andrea LeivaAttilio Rigotti
Mar 1, 2007·Journal of Clinical Lipidology·Ronald B Goldberg, Armando J Mendez
Sep 5, 2009·Biochimica Et Biophysica Acta·Mohammad Anwar HossainShinji Yokoyama
Feb 17, 2009·Endocrinology and Metabolism Clinics of North America·Peter P Toth
Jan 27, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jiyoung LeeJongsook Kim Kemper
May 7, 2008·Biochemical and Biophysical Research Communications·Miki TakahashiRyuichiro Sato
Aug 21, 2007·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Stefan P J DullensRonald P Mensink
Apr 7, 2007·Trends in Pharmacological Sciences·Bertrand Cariou, Bart Staels
Nov 18, 2006·Biochimica Et Biophysica Acta·Grace L GuoFrank J Gonzalez
Dec 30, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Martijn O HoekeKlaas Nico Faber
Nov 6, 2012·International Journal of Cancer. Journal International Du Cancer·Stefania CatalanoSebastiano Andò
Jul 15, 2011·Wiley Interdisciplinary Reviews. Systems Biology and Medicine·Michele VaccaAntonio Moschetta

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
ELISA
transfection
FCS
electrophoresis

Software Mentioned

SPSS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.